Core A is organized to meet demonstrated statistical needs of participating scientists in the areas of biostatistical design and analysis, and data management. Please see the Appendix for additional descriptions of biostatistical methodology. The objectives of Core A are as follows: 1. To assist in the biostatistical design of clinical and laboratory studies in this Program Project Grant (PPG). 2. To assist in the analysis of research data. In this role, the core provides assistance to multiple investigators in implementing study protocol design, data entry, data monitoring and analysis and manuscript w r i t i n g . 3. To provide experienced staff to carry out analyses. 4. To assist investigators in all aspects of data management including the organization of their data flow and in the choice and setup of data base management systems. 5. To develop biostatistical methodology for statistical problems arising in this PPG. 6: To provide scientific input more generally as a member of the Executive Committee.
Core A will support all three projects and work closely with other Cores, especially with respect to analyzing data from the trial in combination with the archival patient material. To develop further support for Projects I, II and III we have been pursuing various statistical methodologies for the handling of incomplete data.
|Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158|
|Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222|
|Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959|
|Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013|
|Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73|
|Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-541|
|Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64|
|Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46|
|Marzese, Diego M; Huang, Sharon K; Hoon, Dave S B (2015) In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues. Methods Mol Biol :|
|Faries, M B; Cochran, A J; Elashoff, R M et al. (2015) Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of t Br J Dermatol 172:571-3|
Showing the most recent 10 out of 255 publications